Sequenom
 |
|
| Subsidiary | |
| Traded as | : SQNM (Former) |
| Industry | Biotechnology |
| Headquarters | San Diego, CA, USA |
|
Key people
|
Dirk van den Boom (CEO) |
| Products | MaterniT21 PLUS, MaterniT GENOME, VisibiliT, HerediT CF, HerediT UNIVERSAL, NextView, SensiGene RHD |
| Services | Non-Invasive Prenatal Testing (NIPT), Carrier Screening |
| Parent | LabCorp |
| Website | Official site |
Sequenom (NASDAQ: SQNM) is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT and carrier screening. Sequenom's wholly owned subsidiarity, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, HerediT CF Cystic Fibrosis screening test, and the SensiGene RHD Fetal RHD genotyping test.
In June 2014 the company sold its biosciences unit to Agena Bioscience for up to $35.8 million. In July 2016, it was announced that diagnostic and testing giant LabCorp will acquire Sequenom, paying $2.40 for every outstanding share of Sequenom stock. The sale has been approved by the board of directors but still needs to be approved by shareholders.
Companies also offering non-invasive prenatal genetic testing include Ariosa,Ravgen,Illumina (Verinata Health), and Natera (The Panorama Prenatal Test),. Other companies and universities that are working towards developing non-invasive prenatal testing include Stanford University,.
In January 2012, Sequenom entered a patent battle with competing companies, Ariosa and Natera, accusing them of infringing the "540 patent" (US 6258540). The cases are Sequenom Inc. v. Natera Inc. 12-cv-0184, Sequenom v. Ariosa Diagnostics Inc., 12-cv-0189, U.S. District Court, Southern District of California (San Diego), and Ariosa v. Sequenom.
...
Wikipedia